MedTrace Logo

Brinzolamide for the Treatment of Chronic Central Serous Chorioretinopathy

NCT03542006 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 35

Last updated 2018-05-31

No results posted yet for this study

Summary

Examine the efficacy of brinzolamide for the treatment of central serous chorioretinopathy

Conditions

  • Central Serous Chorioretinopathy

Interventions

DRUG

Brinzolamide Ophthalmic

Topical brinzolamide given bd for 3 months

Sponsors & Collaborators

  • Tel-Aviv Sourasky Medical Center

    lead OTHER_GOV

Principal Investigators

  • Dinah Zur · Tel-Aviv Sourasky Medical Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-06-01
Primary Completion
2019-01-01
Completion
2019-04-01

Countries

  • Argentina
  • Israel

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03542006 on ClinicalTrials.gov